MediPharm Labs Corp.
MEDIF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.39 | -0.00 | 0.33 | 0.10 |
| FCF Yield | -0.52% | -9.95% | -7.61% | -4.51% |
| EV / EBITDA | -13.61 | -5.52 | 589.15 | -11.67 |
| Quality | ||||
| ROIC | -5.72% | -9.42% | -1.02% | -4.14% |
| Gross Margin | 22.38% | 28.20% | 38.70% | 30.03% |
| Cash Conversion Ratio | 0.07 | 0.73 | 7.78 | 0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | 15.99% | 16.24% | 23.04% | 23.80% |
| Free Cash Flow Growth | 93.81% | 7.96% | -174.89% | -59.86% |
| Safety | ||||
| Net Debt / EBITDA | 5.96 | 2.94 | -154.04 | 9.88 |
| Interest Coverage | -136.75 | -316.67 | -27.56 | -85.86 |
| Efficiency | ||||
| Inventory Turnover | 1.10 | 0.91 | 0.63 | 0.97 |
| Cash Conversion Cycle | 94.81 | 111.37 | 142.41 | 103.92 |